{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:48:45Z","timestamp":1793944125179,"version":"4.8.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-58435-9","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T07:51:20Z","timestamp":1743753080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5779-2593","authenticated-orcid":false,"given":"Dongliang","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1759-9147","authenticated-orcid":false,"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhida","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangdong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5595-3103","authenticated-orcid":false,"given":"Lele","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8249-968X","authenticated-orcid":false,"given":"Wenxin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gening","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1771-7545","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"58435_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw, P. et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J. Thorac. Oncol. 11, 39\u201351 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"58435_CR2","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour, K. C. & Riely, G. J. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. Jama. 322, 764\u2013774 (2019).","journal-title":"Jama"},{"key":"58435_CR3","first-page":"15460","volume":"367","author":"Y Zhao","year":"2019","unstructured":"Zhao, Y. et al. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ. 367, 15460 (2019).","journal-title":"BMJ"},{"key":"58435_CR4","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel, D. R. et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J. Clin. Oncol. 40, 1301\u20131311 (2022).","journal-title":"J. Clin. Oncol."},{"key":"58435_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 23, 209\u2013219 (2022).","journal-title":"Lancet Oncol."},{"key":"58435_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","volume":"18","author":"N Girard","year":"2023","unstructured":"Girard, N. et al. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J. Thorac. Oncol. 18, 181\u2013193 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"58435_CR7","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. J. Clin. Oncol. 40, 3162\u20133171 (2022).","journal-title":"J. Clin. Oncol."},{"key":"58435_CR8","doi-asserted-by":"crossref","unstructured":"Lu, S. et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N. Engl. J. Med. 391, 585\u2013597 (2024).","DOI":"10.1056\/NEJMoa2402614"},{"key":"58435_CR9","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu, Y. L. et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N. Engl. J. Med. 383, 1711\u20131723 (2020).","journal-title":"N. Engl. J. Med"},{"key":"58435_CR10","doi-asserted-by":"crossref","unstructured":"Blakely, C. M. et al. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. J. Clin. Oncol. 42, 3105\u20133114 (2024).","DOI":"10.1200\/JCO.24.00071"},{"key":"58435_CR11","doi-asserted-by":"crossref","unstructured":"Bian, D. et al. Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study. Nat. Commun. 14, 4655 (2023).","DOI":"10.1038\/s41467-023-40349-z"},{"key":"58435_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","volume":"178","author":"C Lv","year":"2023","unstructured":"Lv, C. et al. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial. Lung Cancer 178, 151\u2013156 (2023).","journal-title":"Lung Cancer"},{"key":"58435_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41392-022-01286-3","volume":"8","author":"WZ Zhong","year":"2023","unstructured":"Zhong, W. Z. et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal Transduct. Target Ther. 8, 76 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"58435_CR14","doi-asserted-by":"crossref","unstructured":"Lee, J. B. et al. Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA). J. Thorac Oncol. 24, 02544-9 (2024).","DOI":"10.1016\/j.jtho.2024.12.023"},{"key":"58435_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40265-022-01695-2","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley, M. & Keam, S. J. Aumolertinib: A Review in Non-Small Cell Lung Cancer. Drugs 82, 577\u2013584 (2022).","journal-title":"Drugs"},{"key":"58435_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.872225","volume":"12","author":"S Feng","year":"2022","unstructured":"Feng, S. et al. Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series. Front Oncol. 12, 872225 (2022).","journal-title":"Front Oncol."},{"key":"58435_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08266-w","volume":"21","author":"L Zhu","year":"2021","unstructured":"Zhu, L. et al. Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study. BMC Cancer 21, 511 (2021).","journal-title":"BMC Cancer"},{"key":"58435_CR18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1126\/science.285.5428.730","volume":"285","author":"J Wu","year":"1999","unstructured":"Wu, J. et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285, 730\u2013732 (1999).","journal-title":"Science"},{"key":"58435_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/312641a0","volume":"312","author":"MC Mingari","year":"1984","unstructured":"Mingari, M. C. et al. Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature 312, 641\u2013643 (1984).","journal-title":"Nature"},{"key":"58435_CR20","doi-asserted-by":"publisher","first-page":"15670","DOI":"10.1074\/jbc.M115.646422","volume":"290","author":"Y Yang","year":"2015","unstructured":"Yang, Y. et al. The Us3 Protein of Herpes Simplex Virus 1 Inhibits T Cell Signaling by Confining Linker for Activation of T Cells (LAT) Activation via TRAF6 Protein. J. Biol. Chem. 290, 15670\u201315678 (2015).","journal-title":"J. Biol. Chem."},{"key":"58435_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."},{"key":"58435_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"58435_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0638-6","volume":"11","author":"F Finotello","year":"2019","unstructured":"Finotello, F. et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 11, 34 (2019).","journal-title":"Genome Med."},{"key":"58435_CR24","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013w514 (2020).","journal-title":"Nucleic Acids Res."},{"key":"58435_CR25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865.e847 (2021).","journal-title":"Cancer Cell"},{"key":"58435_CR26","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/ijc.32191","volume":"145","author":"Y Jia","year":"2019","unstructured":"Jia, Y. et al. EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies. Int J. Cancer 145, 1432\u20131444 (2019).","journal-title":"Int J. Cancer"},{"key":"58435_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","volume":"7","author":"A Osipov","year":"2019","unstructured":"Osipov, A., Saung, M. T., Zheng, L. & Murphy, A. G. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. J. Immunother. Cancer 7, 224 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"58435_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41588-019-0569-6","volume":"52","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat. Genet. 52, 177\u2013186 (2020).","journal-title":"Nat. Genet."},{"key":"58435_CR29","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41416-020-01032-y","volume":"123","author":"R Yang","year":"2020","unstructured":"Yang, R. et al. E2F7-EZH2 axis regulates PTEN\/AKT\/mTOR signalling and glioblastoma progression. Br. J. Cancer 123, 1445\u20131455 (2020).","journal-title":"Br. J. Cancer"},{"key":"58435_CR30","doi-asserted-by":"crossref","unstructured":"Arora, S. et al. Unravelling the Role of miR-20b-5p, CCNB1, HMGA2 and E2F7 in Development and Progression of Non-Small Cell Lung Cancer (NSCLC). Biology (Basel) 9, 201 (2020).","DOI":"10.3390\/biology9080201"},{"key":"58435_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semcancer.2019.08.007","volume":"67","author":"D Novak","year":"2020","unstructured":"Novak, D. et al. SOX2 in development and cancer biology. Semin Cancer Biol. 67, 74\u201382 (2020).","journal-title":"Semin Cancer Biol."},{"key":"58435_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.792","volume":"12","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS\/STING signalling in non-small cell lung cancer. Clin. Transl. Med. 12, e792 (2022).","journal-title":"Clin. Transl. Med"},{"key":"58435_CR33","doi-asserted-by":"crossref","unstructured":"Pervizaj-Oruqaj, L., Ferrero, M. R., Matt, U. & Herold, S. The guardians of pulmonary harmony: alveolar macrophages orchestrating the symphony of lung inflammation and tissue homeostasis. Eur. Respir. Rev. 33, 230263 (2024).","DOI":"10.1183\/16000617.0263-2023"},{"key":"58435_CR34","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1158\/0008-5472.CAN-14-3167","volume":"75","author":"CA Eberlein","year":"2015","unstructured":"Eberlein, C. A. et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Res. 75, 2489\u20132500 (2015).","journal-title":"Cancer Res"},{"key":"58435_CR35","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","volume":"30","author":"C Luchini","year":"2019","unstructured":"Luchini, C. et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann. Oncol. 30, 1232\u20131243 (2019).","journal-title":"Ann. Oncol."},{"key":"58435_CR36","doi-asserted-by":"crossref","unstructured":"Yu, Z., Xu, F. & Zou, J. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis. Eur. J. Clin. Pharmacol. 80, 505\u2013517 (2024).","DOI":"10.1007\/s00228-024-03620-w"},{"key":"58435_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 378, 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"key":"58435_CR38","doi-asserted-by":"crossref","unstructured":"Shi, Y. et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir. Medicine. 10, 1019\u20131028 (2022).","DOI":"10.1016\/S2213-2600(22)00168-0"},{"key":"58435_CR39","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.athoracsur.2021.11.010","volume":"114","author":"WG Andrews","year":"2022","unstructured":"Andrews, W. G. et al. Persistent N2 After Induction Is Not a Contraindication to Surgery for Lung Cancer. Ann. Thorac. Surg. 114, 394\u2013400 (2022).","journal-title":"Ann. Thorac. Surg."},{"key":"58435_CR40","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist, L. V. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327\u20133334 (2013).","journal-title":"J. Clin. Oncol."},{"key":"58435_CR41","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.canlet.2008.02.064","volume":"265","author":"JQ Zhu","year":"2008","unstructured":"Zhu, J. Q. et al. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett. 265, 307\u2013317 (2008).","journal-title":"Cancer Lett."},{"key":"58435_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216848","volume":"591","author":"L Zheng","year":"2024","unstructured":"Zheng, L. et al. FBXO43 promotes cell cycle progression in cancer cells through stabilizing SKP2. Cancer Lett. 591, 216848 (2024).","journal-title":"Cancer Lett."},{"key":"58435_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/12013","volume":"1","author":"AC Carrano","year":"1999","unstructured":"Carrano, A. C., Eytan, E., Hershko, A. & Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1, 193\u2013199 (1999).","journal-title":"Nat. Cell Biol."},{"key":"58435_CR44","doi-asserted-by":"publisher","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine 62, 102106 (2023).","journal-title":"EClinicalMedicine"},{"key":"58435_CR45","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","volume":"11","author":"S Lu","year":"2023","unstructured":"Lu, S. et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 11, 624\u2013636 (2023).","journal-title":"Lancet Respir. Med"},{"key":"58435_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","volume":"17","author":"N Nogami","year":"2022","unstructured":"Nogami, N. et al. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. J. Thorac. Oncol. 17, 309\u2013323 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"58435_CR47","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1158\/1078-0432.CCR-19-2027","volume":"26","author":"K Isomoto","year":"2020","unstructured":"Isomoto, K. et al. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer. Clin. Cancer Res. 26, 2037\u20132046 (2020).","journal-title":"Clin. Cancer Res"},{"key":"58435_CR48","doi-asserted-by":"crossref","unstructured":"Lu, C. et al. Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect. J. Immunother Cancer 12, e009165 (2024).","DOI":"10.1136\/jitc-2024-009165"},{"key":"58435_CR49","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jtho.2018.11.028","volume":"14","author":"JC Yang","year":"2019","unstructured":"Yang, J. C. et al. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J. Thorac. Oncol. 14, 553\u2013559 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"58435_CR50","doi-asserted-by":"publisher","first-page":"14209","DOI":"10.18632\/oncotarget.3694","volume":"6","author":"Y Tang","year":"2015","unstructured":"Tang, Y. et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 6, 14209\u201314219 (2015).","journal-title":"Oncotarget"},{"key":"58435_CR51","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard, D. et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N. Engl. J. Med. 389, 1935\u20131948 (2023).","journal-title":"N. Engl. J. Med."},{"key":"58435_CR52","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2021.02.025","volume":"154","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer 154, 176\u2013185 (2021).","journal-title":"Lung Cancer"},{"key":"58435_CR53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-024-01861-w","volume":"9","author":"H Xia","year":"2024","unstructured":"Xia, H. et al. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study. Signal Transduct. Target Ther. 9, 145 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"58435_CR54","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1200\/JCO.19.00075","volume":"37","author":"W Zhong","year":"2019","unstructured":"Zhong, W. et al. EGFRErlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 37, 2235\u20132245 (2019).","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"58435_CR55","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jtho.2021.10.024","volume":"17","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. J. Thorac. Oncol. 17, 411\u2013422 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"58435_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.107","volume":"2","author":"S Chen","year":"2023","unstructured":"Chen, S. Ultrafast one-pass FASTQ data preprocessing, quality control, and deduplication using fastp. Imeta 2, e107 (2023).","journal-title":"Imeta"},{"key":"58435_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"58435_CR58","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"58435_CR59","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"58435_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"58435_CR61","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"58435_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58435-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58435-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58435-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T20:16:35Z","timestamp":1743797795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58435-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58435"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58435-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3143"}}